A case of complex partial status epilepticus (CPSE) with high dose treatment of tiagabine (TGB) is reported. Seizure aggravation and CPSE developed after stepwise increase of TGB to a dose of 60 mg per day as add-on treatment to carbamazepine (CBZ) 1200 mg/day and vigabatrine (VGB) 1000 mg/day. The EEG during CPSE showed bilateral rhythmic slow activity. Clinical symptoms of CPSE and the EEG normalized after i.v. treatment with clonazepam. The literature and the possible mechanism of this paradoxical phenomenon are discussed.
Introduction
Paradoxical seizure exacerbation and induction of status epilepticus (SE) by conventional epileptic drugs have been reported for CBZ 1 , carbamazepine-10, 11-epoxide (CBZ-E) 2 and phenytoin (PHE) 3 .
Tiagabine (TGB), a nipecotic acid analogue, is a new antiepileptic drug which inhibits neuronal and glial GABA uptake 4 . It is effective in partial seizures with and without secondary generalization 5 . Although TGB has only mild side effects on the central nervous system 6 , there are two recent case reports with paradoxical aggravation of seizures leading to non-convulsive status epilepticus 7, 8 . These findings were contrasted by the work of Shinnar and co-workers 9 who argued that the incidence of SE in TGB-treated patients is not higher than the expected incidence in non-TGB-treated patients in randomized trials and population-based external cohorts [10] [11] [12] [13] . In this report, we describe another patient with seizure exacerbation and CPSE with TGB as add-on treatment to CBZ and VGB, discuss the literature and the possible pathophysiology of this paradoxical phenomenon.
Case report
A 21-year-old woman presented in a confusional state with partial responsiveness and complete amnesia for at least 5 hours. Her symptoms developed while she was on stepwise increase of TGB during the previous 2 months as add-on treatment to VGB 1000 mg/day and CBZ 1200 mg/day. Two weeks before admission she was on 30 mg TGB b.i.d. which led to an increase in seizure frequency from two per month to five per week. She was admitted to hospital in a confusional state with partial responsiveness, disturbed balance and gait ataxia interrupted by short erratic myoclonic jerks of the extremities. The EEG showed diffuse generalized bilateral synchronous slow activity (Fig. 1) . Following intravenous infusion of 2 mg clonazepam there was an instantaneous change of the clinical picture: she became fully responsive, with cessation of involuntary movements, normal gait and normalization of the EEG (Fig. 2) . She had complete retrograde amnesia for at least 5 hours. TGB was withdrawn and clonazepam 2 mg t.i.d. was added to CBZ 1200 mg per day. She made a complete recovery, experiencing her previous seizure frequency of about two per month.
She was the third child of healthy parents with no family history of epilepsy. Pregnancy and birth were normal and the developmental milestones reached within the normal limits. At the age of 8, partial seizures began with clonic jerking of the left leg, which initially responded well to CBZ leading to total seizure control from age 15 to 17, followed by a stepwise reduction of CBZ. During the withdrawal period seizures recurred: she experienced an aura with the feeling of movement in the legs without visible jerking, followed by slight clonic jerking of the left or right leg with preserved consciousness. CBZ was reinstituted but seizures persisted with a frequency of five to 10 per month. The EEG showed blunt sharp waves over the left frontal region (Fig. 3) .
At the age of 18 she experienced seizures with jerking of both legs during the night with preserved consciousness. CBZ was increased to 1200 mg but seizure frequency remained high with nocturnal clustering. The interictal EEG revealed diffuse slowing with very infrequent left frontal sharp wave activity. Findings on magnetic resonance imaging (MRI) were normal, but interictal Tc 99 -HMPAO SPECT demonstrated a decreased signal in the left frontal region. Formal psychometric testing revealed a below average IQ of 87 on the Wechsler Scale (HAWIE) 14 , and speed performance in the trail matching test 15 was below average. At 19 years old VGB was added up to 2000 mg without success. One year later VGB was reduced to 1000 mg and TGB was added, starting with 5 mg b.i.d. which attenuated her seizure frequency from 10 per month with nocturnal clustering to 2 per month.
Discussion
The reported patient presented with a prolonged episode of confusion, partial responsiveness and amnesia for at least 5 hours which was diagnosed and confirmed by ictal EEG as complex partial status epilepticus. To our knowledge this is the first report of CPSE with TGB which is documented by EEG. The EEG findings were consistent with the previously described highly variable patterns 16 .
The symptoms occurred during the stepwise increase of TGB at a dose of 60 mg/day. In the previously reported cases the symptoms occurred at 30 mg/day in one case 8 , 48 mg/day in one case and 60 mg/day in two cases 7 . The co-medication was CBZ in a dose of 1200 mg to 1500 mg/day and lamotrigine (LTG) in a dose of 100 mg to 400 mg/day in three cases, and PHE 350 mg/day in another case 7, 8 . In the reported case the co-medication was CBZ 1200 mg/day and VGB 1000 mg/day.
Shinnar evaluated the incidence of SE and CPSE in the TGB-treated patients of all clinical trials 9 . In the placebo-controlled trials, the overall incidence of CPSE was similar in the TGB-treated patients and the placebo control group (0.2% vs. 0.0%). However, in the monotherapy studies, the high dose treatment group on 36 mg/day experienced more CPSE than the low dose treatment group on 6 mg/day (4% vs. 0%, P = 0.054). None of these patients received as high dosage levels as four of the five reported patients with CPSE including the presented one (48 mg to 60 mg/day). In addition to that, the presented case received VGB, which enhances GABA-ergic activity by blocking the GABAtransaminase 17 .
In one study of CPSE, the most common precipitants were generalized tonic-clonic seizures (GTC) and changes in antiepileptic drugs, either because of non-compliance or under medical direction 18 . Only in case one of Schapel's series 7 was there a discontinuation of CBZ, which could have led to an increase in seizure frequency and CPSE, despite its cautious rate of withdrawal.
A recent study related CPSE to increased of CBZ-E secondary to co-medication 2 . Gustavson and coworkers showed that TGB caused no significant changes in CBZ or CBZ-E levels when added under steady-state pharmacokinetics 19 .
At the neurochemical level, abrupt withdrawal of GABA-ergic activity may result in generalized convulsions or electrographic activity in animals 20 . TGB acts as a specific GABA-uptake inhibitor thereby enhancing GABA-ergic activity. TGB is 2.5 times more potent in inhibiting glial, as opposed to neuronal, GABA uptake 21 . At high doses TGB may block all GABA uptake and therefore depleting intracellular GABA possibly leading to an attenuation of the anticonvulsant properties of TGB. In animal experiments TGB shows a biphasic dose-response curve against methyl-6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM)-induced clonic convulsions (in mice) and pentylenetetrazol (PTZ)-induced clonic and tonic convulsions (in mice and rats) with an attenuated anticonvulsant effect at higher doses 22 . However, TGB lacks proconvulsant or convulsant activity even in doses up to 100 mg/kg i.p. in chemically kindled mice 4 . To date, the mechanism of seizure exacerbation by TGB seems unclear.
In summary, we reported the clinical and EEG findings of a patient, who developed CPSE with TGB and want to draw attention to the possible seizure precipitating effect of TGB in high doses of more than 40 mg per day.
